Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib Dose Escalation in Japanese Relapsed/Refractory AML
jRCT2080223088Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum tolerated dose of quizartinib and Safety and tolerability of quizartinib. Started Jan 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223088.